Working Capital Management Seizes Priority in North American and European Pharma Industry

Firms realize that boosting working capital efficiency can offset the market's current challenges, finds Frost & Sullivan

Jul 29, 2015, 07:30 ET from Frost & Sullivan

MOUNTAIN VIEW, Calif., July 29, 2015 /PRNewswire/ -- Efforts to improve working capital efficiency are becoming entrenched in the growth strategy of pharmaceutical firms in North America and Europe. The realization is that an effective working capital management will ease the difficulties caused by low sales, pricing pressures and patent cliffs. Big pharma companies expect to invest in optimizing working capital efficiency to bolster returns.

Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO

Analysis from Frost & Sullivan, Working Capital Management in the North American and European Pharmaceutical Industry (https://www.frost.com/neaf), reveals companies in the U.S. effectively managed to reduce the cash conversion cycle by 44.2 percent between 2012 and 2013. European companies were not as successful, managing to reduce the cash conversion cycle by 26.2 percent between 2012 and 2013. The cash conversion cycle is an indicator of working capital efficiency.

For complimentary access to more information on this research, please visit: http://bit.ly/1bKUs6c.

"Business models in the North American and European pharmaceutical industry are evolving; placing emphasis on achieving working capital efficiency by focusing on outsourced manufacturing and new market entry," said Frost & Sullivan Senior Research Analyst Saneesh Edacherian.

The following issues highlight the importance of effective working capital management.

Decreasing Profitability: Global economic slowdowns, expiring blockbuster drug patents, intensifying competition and lowering public spending on drugs affect the profitability of participants in the pharma and biotech industry, spurring the need for effective working capital management.

Fizzling Innovation Model: Leading pharmaceutical manufacturers are facing a twofold crisis. The number of blockbuster drugs about to lose their patents is alarmingly high, and pipelines are empty. With no new sources of revenue emerging, cutting costs through working capital management is crucial to optimize expenses.

Price Premium Pressure: Strict regulations and diverse healthcare models across geographies are compelling drug companies to cut costs, making working capital management a necessary ingredient in their strategic mix to sustain profits.

Access to New Markets: Working capital management will gain further significance as major market participants in North America and Europe look to developing economies for merger and acquisition opportunities.

"Chinese, Indian and Latin American countries constitute large unexplored markets for drug makers," concluded Edacherian. "The development of research centers and manufacturing plants will require adept working capital management, and a surefire way to ensure a smooth entry into these regions."

Working Capital Management in the North American and European Pharmaceutical Industry is part of the Business and Financial Services (http://ww2.frost.com/research/industry/business-financial-services) subscription. Frost & Sullivan's related studies include: Funding Patterns in the Global Pharma and Biotech Industry, Mergers and Acquisitions in the Global Life and Health Insurance Industry and US Healthcare Real Estate Investment Trusts Industry. All studies included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan's Business and Financial Services group serves clients around the world in all aspects of financial analysis, market research and monitoring, due diligence, idea generation, opportunity analysis, investment valuation and other proprietary research.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Working Capital Management in the North American and European Pharmaceutical Industry
NEAF-F1

Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: kayla.belcher@frost.com

http://www.frost.com

 

SOURCE Frost & Sullivan



RELATED LINKS

http://www.frost.com